Id: | acc3648 |
Group: | 1sens |
Protein: | pRb |
Gene Symbol: | RB1 |
Protein Id: | P06400 |
Protein Name: | RB_HUMAN |
PTM: | phosphorylation |
Site: | Thr252 |
Site Sequence: | VIPINGSPRTPRRGQNRSARI |
Disease Category: | Cancer |
Disease: | Leukemia |
Disease Subtype: | Myeloid Leukemia |
Disease Cellline: | MV4-11 |
Disease Info: | |
Drug: | Transforming growth factor beta |
Drug Info: | "Transforming growth factor beta is a cytokine that plays a crucial role in various cellular processes such as cell growth, differentiation, and apoptosis." |
Effect: | no effect |
Effect Info: | Transforming growth factor beta dephosphorylates pRB in tumor cells. |
Note: | no effect |
Score: | 2.0 |
Pubmed(PMID): | 11027571 |
Sentence Index: | 11027571_0 |
Sentence: | Transforming growth factor beta inhibits the phosphorylation of pRB at multiple serine/threonine sites and differentially regulates the formation of pRB family-E2F complexes in human myeloid leukemia cells. |
Sequence & Structure:
MPPKTPRKTAATAAAAAAEPPAPPPPPPPEEDPEQDSGPEDLPLVRLEFEETEEPDFTALCQKLKIPDHVRERAWLTWEKVSSVDGVLGGYIQKKKELWGICIFIAAVDLDEMSFTFTELQKNIEISVHKFFNLLKEIDTSTKVDNAMSRLLKKYDVLFALFSKLERTCELIYLTQPSSSISTEINSALVLKVSWITFLLAKGEVLQMEDDLVISFQLMLCVLDYFIKLSPPMLLKEPYKTAVIPINGSPRTPRRGQNRSARIAKQLENDTRIIEVLCKEHECNIDEVKNVYFKNFIPFMNSLGLVTSNGLPEVENLSKRYEEIYLKNKDLDARLFLDHDKTLQTDSIDSFETQRTPRKSNLDEEVNVIPPHTPVRTVMNTIQQLMMILNSASDQPSENLISYFNNCTVNPKESILKRVKDIGYIFKEKFAKAVGQGCVEIGSQRYKLGVRLYYRVMESMLKSEEERLSIQNFSKLLNDNIFHMSLLACALEVVMATYSRSTSQNLDSGTDLSFPWILNVLNLKAFDFYKVIESFIKAEGNLTREMIKHLERCEHRIMESLAWLSDSPLFDLIKQSKDREGPTDHLESACPLNLPLQNNHTAADMYLSPVRSPKKKGSTTRVNSTANAETQATSAFQTQKPLKSTSLSLFYKKVYRLAYLRLNTLCERLLSEHPELEHIIWTLFQHTLQNEYELMRDRHLDQIMMCSMYGICKVKNIDLKFKIIVTAYKDLPHAVQETFKRVLIKEEEYDSIIVFYNSVFMQRLKTNILQYASTRPPTLSPIPHIPRSPYKFPSSPLRIPGGNIYISPLKSPYKISEGLPTPTKMTPRSRILVSIGESFGTSEKFQKINQMVCNSDRVLKRSAEGSNPPKPLKKLRFDIEGSDEADGSKHLPGESKFQQKLAEMTSTRTRMQKQKMNDSMDTSNKEEK
Select PDB:
No data.
Protein Tractability:
source: Open TargetsPTM Intensity:
source: CPTACRB1-Thr252 | |
---|---|
Cancer | Intensity |
BRCA | |
COAD | -0.392 |
HGSC | 0.883 |
ccRCC | |
GBM | 0.465 |
HNSC | 0.788 |
LUAD | -1.849 |
LUSC | 1.098 |
non_ccRCC | |
PDAC | -0.735 |
UCEC | -0.259 |
PTM-Disease Association:
source: PTMDResidue | Position | State | Disease | Class | PMID |
---|---|---|---|---|---|
T | 252 | U | Breast cancer/tumor/carcinoma | Phosphorylation | 17599043 |
State Note: Based on the distinct PTM states in diseases, PTMD classified all disease-associated PTMs into six classes, including whether the up-regulation (U) or down-regulation (D) of PTM levels, the absence (A) or presence (P) of PTMs, and the creation (C) or disruption (N) of PTM sites are associated with diseases.
PTM-Drug Perturbation Response:
source: DecryptMProtein | Gene | PTM | Position | Modified sequence | Cell | Drug | pEC50 | Regulation | Experiment |
---|---|---|---|---|---|---|---|---|---|
P06400 | RB1 | P | Ser249;Thr252 | TAVIPINGS(ph)PRT(ph)PR | A431 | Gefitinib | 8.8586 | - | |
P06400 | RB1 | P | Thr252 | TAVIPINGSPRT(ph)PR | A549 | Tideglusib | 6.7698 | - | |
P06400 | RB1 | P | Ser249;Thr252 | TAVIPINGS(ph)PRT(ph)PR | A549 | Staursporin | 7.642 | - | |
P06400 | RB1 | P | Ser249;Thr252 | TAVIPINGS(ph)PRT(ph)PR | A549 | PD325901 | 10.6071 | - | |
P06400 | RB1 | P | Ser249;Thr252 | TAVIPINGS(ph)PRT(ph)PR | A549 | Dasatinib | 8.7717 | - | |
P06400 | RB1 | P | Thr252 | TAVIPINGSPRT(ph)PR | A549 | Dasatinib | 8.9576 | - | |
P06400 | RB1 | P | Thr252 | TAVIPINGSPRT(ph)PR | A549 | Dactolisib | 5.5441 | - | |
P06400 | RB1 | P | Ser249;Thr252 | TAVIPINGS(ph)PRT(ph)PR | A549 | Dactolisib | 6.1766 | - | |
P06400 | RB1 | P | Thr252 | TAVIPINGSPRT(ph)PR | A549 | AZD8055 | 7.5694 | - | |
P06400 | RB1 | P | Ser249;Thr252 | TAVIPINGS(ph)PRT(ph)PR | A431 | Afatinib | 7.2253 | - | |
P06400 | RB1 | P | Ser249;Thr252 | TAVIPINGS(ph)PRT(ph)PR | A431 | Gefitinib | 8.2497 | - | |
P06400 | RB1 | P | Ser249;Thr252 | TAVIPINGS(ph)PRT(ph)PR | A431 | Gefitinib | 7.9731 | - | |
P06400 | RB1 | P | Ser249;Thr252 | TAVIPINGS(ph)PRT(ph)PR | A431 | Dasatinib | 5.1816 | - | |
P06400 | RB1 | P | Ser249;Thr252 | TAVIPINGS(ph)PRT(ph)PR | A431 | Dasatinib | 7.148 | - | |
P06400 | RB1 | P | Ser249;Thr252 | TAVIPINGS(ph)PRT(ph)PR | A431 | Dasatinib | 6.2497 | - | |
P06400 | RB1 | P | Ser249;Thr252 | TAVIPINGS(ph)PRT(ph)PR | A431 | Afatinib | 7.7579 | - | |
P06400 | RB1 | P | Ser249;Thr252 | TAVIPINGS(ph)PRT(ph)PR | A431 | Afatinib | 7.1355 | - | |
P06400 | RB1 | P | Ser249;Thr252 | TAVIPINGS(ph)PRT(ph)PR | A431 | Afatinib | 8.5301 | - |
pEC50 Note: pEC50 is the negative logarithm of EC50 (half-maximal effective concentration, dosage unit Mol), calculated as pEC50 = -log10(EC50), which quantifies the potency of a drug or compound.
Function score:
source: funscoRNo data.